Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy
ABSTRACT Objective To develop a novel prenatal assay based on selective analysis of cell‐free DNA in maternal blood for evaluation of fetal Trisomy 21 (T21) and Trisomy 18 (T18). Methods Two hundred ninety‐eight pregnancies, including 39 T21 and seven T18 confirmed fetal aneuploidies, were analyzed...
Saved in:
Published in | Prenatal diagnosis Vol. 32; no. 1; pp. 3 - 9 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.01.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ABSTRACT
Objective
To develop a novel prenatal assay based on selective analysis of cell‐free DNA in maternal blood for evaluation of fetal Trisomy 21 (T21) and Trisomy 18 (T18).
Methods
Two hundred ninety‐eight pregnancies, including 39 T21 and seven T18 confirmed fetal aneuploidies, were analyzed using a novel, highly multiplexed assay, termed digital analysis of selected regions (DANSR™). Cell‐free DNA from maternal blood samples was analyzed using DANSR assays for loci on chromosomes 21 and 18. Products from 96 separate patients were pooled and sequenced together. A standard Z‐test of chromosomal proportions was used to distinguish aneuploid samples from average‐risk pregnancy samples. DANSR aneuploidy discrimination was evaluated at various sequence depths.
Results
At the lowest sequencing depth, corresponding to 204 000 sequencing counts per sample, average‐risk cases where distinguished from T21 and T18 cases, with Z statistics for all cases exceeding 3.6. Increasing the sequencing depth to 410 000 counts per sample substantially improved separation of aneuploid and average‐risk cases. A further increase to 620 000 counts per sample resulted in only marginal improvement. This depth of sequencing represents less than 5% of that required by massively parallel shotgun sequencing approaches.
Conclusion
Digital analysis of selected regions enables highly accurate, cost efficient, and scalable noninvasive fetal aneuploidy assessment. © 2012 John Wiley & Sons, Ltd. |
---|---|
Bibliography: | istex:F8CAC2976C2837F15A85F3B8359853D08E090B79 ArticleID:PD2922 ark:/67375/WNG-W9SLLCV8-T ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Authors contributed equally to the work. Conflicts of interest: None declared Funding sources: None |
ISSN: | 0197-3851 1097-0223 |
DOI: | 10.1002/pd.2922 |